Survival benefit of high dose therapy over sequential chemotherapy in poor risk aggressive non-Hodgkin's lymphoma. Final analysis of the prospective LNH87-2 protocol. A gela study.

被引：0
|
作者：
Haioun, C [1 ]
Lepage, E [1 ]
Gisselbrecht, C [1 ]
Salles, G [1 ]
Coiffier, B [1 ]
Brice, P [1 ]
Bosly, A [1 ]
Morel, P [1 ]
Nouvel, C [1 ]
Tilly, H [1 ]
Lederlin, P [1 ]
Sebban, C [1 ]
Briere, J [1 ]
Gaulard, P [1 ]
Reyes, F [1 ]
机构：
[1] Hop Henri Mondor, F-94010 Creteil, France
来源：
BLOOD | 1999年 / 94卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2711
引用
收藏
页码：610A / 610A
页数：1
相关论文
共 50 条
  • [21] Rituximab vs observation after high-dose consolidative first-line chemotherapy (HDC) with autologous stem cell transplantation in poor risk diffuse large B-cell lymphoma.: Final analysis of the LNH98-B3 GELA study.
    Haioun, C
    Mounier, N
    Emile, JF
    Feugier, P
    Coiffier, B
    Tilly, H
    Recher, C
    Fermé, C
    Gabarre, J
    Herbrecht, R
    Morschhauser, F
    Gisselbrecht, C
    BLOOD, 2005, 106 (11) : 200A - 200A
  • [22] VACOP-B versus VACOP-B plus High-Dose Sequential therapy (HDS) for aggressive non-Hodgkin's lymphoma. Interim analysis of a randomised trial.
    Santini, G
    Leoni, P
    Majolino, I
    BONE MARROW TRANSPLANTATION, 2001, 27 : S13 - S13
  • [23] High-dose sequential (RDS) chemotherapy with high-dose ARA-C and Rituximab prolongs the survival of patients with resistant/relapsed B-cell non-Hodgkin's lymphoma.
    Cortelazzo, S
    Rambaldi, A
    Rossi, A
    Oldani, E
    Bellavita, P
    Motta, T
    Barbui, T
    BLOOD, 2002, 100 (11) : 646A - 646A
  • [24] Ancestim (stem cell factor, SCF) in combination with filgrastim can mobilize sufficient peripheral blood progenitor cells (PBPC) to support high-dose salvage chemotherapy and late intensification in relapsing and refractory aggressive non-Hodgkin's lymphoma. A GELA study.
    Haioun, C
    Van Hoof, A
    Thieblemont, C
    Hulin, C
    Mounier, N
    Tilly, H
    Sebban, C
    Ferrant, A
    Allain, A
    Lepage, E
    Osselaer, JC
    Beaujean, F
    Vannerom, H
    Cailliot, C
    Bosly, A
    BLOOD, 2003, 102 (11) : 415B - 415B
  • [25] Role of high-dose therapy and initial response in survival of poor-risk patients with aggressive non-Hodgkin's lymphoma: a retrospective series on 126 patients from a single center
    R Bouabdallah
    D Coso
    R Costello
    VJ Bardou
    D Blaise
    L Xerri
    D Sainty
    D Maraninchi
    JA Gastaut
    Bone Marrow Transplantation, 2000, 25 : 35 - 40
  • [26] Role of high-dose therapy and initial response in survival of poor-risk patients with aggressive non-Hodgkin's lymphoma: a retrospective series on 126 patients from a single center
    Bouabdallah, R
    Coso, D
    Costello, R
    Bardou, VJ
    Blaise, D
    Xerri, L
    Sainty, D
    Maraninchi, D
    Gastaut, JA
    BONE MARROW TRANSPLANTATION, 2000, 25 (01) : 35 - 40
  • [27] A prospective study of intensive induction therapy with high-dose consolidation in patients with aggressive non-Hodgkin's lymphoma and two or three adverse prognostic factors
    Dumontet, C
    Thieblemont, C
    Espinouse, D
    Bouafia, F
    Hequet, O
    Salles, G
    Coiffier, B
    LEUKEMIA, 2000, 14 (12) : 2159 - 2165
  • [28] A prospective study of intensive induction therapy with high-dose consolidation in patients with aggressive non-Hodgkin's lymphoma and two or three adverse prognostic factors
    C Dumontet
    C Thieblemont
    D Espinouse
    F Bouafia
    O Hequet
    G Salles
    B Coiffier
    Leukemia, 2000, 14 : 2159 - 2165
  • [29] High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma:: results of a multicenter phase II study
    Josting, A
    Sieniawski, M
    Glossmann, JP
    Staak, O
    Nogova, L
    Peters, N
    Mapara, M
    Dörken, B
    Ko, Y
    Metzner, B
    Kisro, J
    Diehl, V
    Engertl, A
    ANNALS OF ONCOLOGY, 2005, 16 (08) : 1359 - 1365
  • [30] Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem cell transplantation in poor risk diffuse large B-cell lymphoma.: Final analysis of the LNH98-B3 GELA study
    Haioun, C
    Mounier, N
    Emile, JF
    Feugier, P
    Coiffier, B
    Tilly, H
    Recher, C
    Fermé, C
    Gabarre, J
    Herbrecht, R
    Morschhauser, F
    Gisselbrecht, C
    BONE MARROW TRANSPLANTATION, 2006, 37 : S26 - S26
12345